Osteopontin controls endothelial cell migration in vitro and in excised human valvular tissue from patients with calcific aortic stenosis and controls

Journal of Cellular Physiology

Volumn 226, Issue 8, 2011, Pages 2139-2149

  Poggio, Paolo ^a   Grau, Juan B ^a   Field, Benjamin C ^a   Sainger, Rachana ^a   Seefried, William F ^a   Rizzolio, Flavio ^b,c   Ferrari, Giovanni ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Temple University   (United States)

^c Human Health Foundation   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AORTA STENOSIS; AORTA VALVE DISEASE; ARTICLE; ATHEROSCLEROSIS; CALCIFICATION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LIPID STORAGE; MALE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; CALCINOSIS; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OSTEOPONTIN;

EID: 79955112593     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22549     Document Type: Article

References (43)

1. Bach DS, Radeva JI, Birnbaum HG, Fournier AA, Tuttle EG. 2007. Prevalence, referral patterns, testing, and surgery in aortic valve disease: Leaving women and elderly patients behind? J Heart Valve Dis 16: 362-369.
2. Balmer C, Beghetti M, Fasnacht M, Friedli B, Arbenz U. 2004. Balloon aortic valvoplasty in paediatric patients: Progressive aortic regurgitation is common. Heart 90: 77-81.
3. Beckmann E, Grau JB, Sainger R, Poggio P, Ferrari G. 2010. Insights into the use of biomarkers in calcific aortic valve disease. J Heart Valve Dis 19: 441-452.
4. Chakraborty G, Jain S, Kundu GC. 2008. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 68: 152-161.
5. Chalajour F, Treede H, Ebrahimnejad A, Lauke H, Reichenspurner H, Ergun S. 2004. Angiogenic activation of valvular endothelial cells in aortic valve stenosis. Exp Cell Res 298: 455-464.
6. Chalajour F, Treede H, Gehling UM, Ebrahimnejad A, Boehm DH, Riemer RK, Ergun S, Reichenspurner H. 2007. Identification and characterization of cells with high angiogenic potential and transitional phenotype in calcific aortic valve. Exp Cell Res 313: 2326-2335.
7. Collett GD, Canfield AE. 2005. Angiogenesis and pericytes in the initiation of ectopic calcification. Circ Res 96: 930-938.
8. Cowell SJ, Newby DE, Boon NA, Elder AT. 2004. Calcific aortic stenosis: Same old story? Age Ageing 33: 538-544.
9. Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, Cai J, Lu B, Li B, Zhang D, Kang Y, Tan M, Qian W, Guo Y. 2009. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 28: 3412-3422.
10. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. 2001. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107: 1055-1061.
11. El-Hamamsy I, Balachandran K, Yacoub MH, Stevens LM, Sarathchandra P, Taylor PM, Yoganathan AP, Chester AH. 2009. Endothelium-dependent regulation of the mechanical properties of aortic valve cusps. J Am Coll Cardiol 53: 1448-1455.
12. Ergun S, Kilik N, Ziegeler G, Hansen A, Nollau P, Gotze J, Wurmbach JH, Horst A, Weil J, Fernando M, Wagener C. 2000. CEA-related cell adhesion molecule 1: A potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell 5: 311-320.
13. Ferrara N. 1999. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77: 527-543.
14. Ferrara N, Davis-Smyth T. 1997. The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25.
15. Freeman RV, Otto CM. 2005. Spectrum of calcific aortic valve disease: Pathogenesis, disease progression, and treatment strategies. Circulation 111: 3316-3326.
16. Gericke A, Qin C, Spevak L, Fujimoto Y, Butler WT, Sorensen ES, Boskey AL. 2005. Importance of phosphorylation for osteopontin regulation of biomineralization. Calcif Tissue Int 77: 45-54.
17. Goldbarg SH, Elmariah S, Miller MA, Fuster V. 2007. Insights into degenerative aortic valve disease. J Am Coll Cardiol 50: 1205-1213.
18. Gu X, Masters KS. 2010. Regulation of valvular interstitial cell calcification by adhesive peptide sequences. J Biomed Mater Res A 93: 1620-1630.
19. Jono S, Peinado C, Giachelli CM. 2000. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 275: 20197-20203.
20. Mohler ER III, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. 2001. Bone formation and inflammation in cardiac valves. Circulation 103: 1522-1528.
21. Nicosia MA, Cochran RP, Einstein DR, Rutland CJ, Kunzelman KS. 2003. A coupled fluid-structure finite element model of the aortic valve and root. J Heart Valve Dis 12: 781-789.
22. Northrup WF III, Dubois KA, Kshettry VR, Teskey JM, Nicoloff DM. 2002. Trends in aortic valve surgery in a large multi-surgeon, multi-hospital practice, 1979-1999. J Heart Valve Dis 11: 768-778; discussion 778-779.
23. O'Brien KD, Kuusisto J, Reichenbach DD, Ferguson M, Giachelli C, Alpers CE, Otto CM. 1995. Osteopontin is expressed in human aortic valvular lesions. Circulation 92: 2163-2168.
24. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. 1996. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 16: 523-532.
25. Okamoto H. 2007. Osteopontin and cardiovascular system. Mol Cell Biochem 300: 1-7.
26. Olsson M, Thyberg J, Nilsson J. 1999. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 19: 1218-1222.
27. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. 1994. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90: 844-853.
28. Pastor-Perez F, Marin F. 2009. Hypertension, aortic sclerosis and the prothrombotic state: Understanding the complex interaction. J Hum Hypertens 23: 287-288.
29. Perin MA, Brito FS, Jr., Almeida BO, Pereira MA, Abizaid A, Tarasoutchi F, Grube E. 2009. Percutaneous aortic valve replacement for the treatment of aortic stenosis: Early experience in Brazil. Arq Bras Cardiol 93: 299-306.
30. Rajamannan NM. 2005. Calcific aortic stenosis: Medical and surgical management in the elderly. Curr Treat Options Cardiovasc Med 7: 437-442.
31. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. 2003. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107: 2181-2184.
32. Rittling SR, Chambers AF. 2004. Role of osteopontin in tumour progression. Br J Cancer 90: 1877-1881.
33. Saad FA, Salih E, Glimcher MJ. 2008. Identification of osteopontin phosphorylation sites involved in bone remodeling and inhibition of pathological calcification. J Cell Biochem 103: 852-856.
34. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M. 1996. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149: 293-305.
35. Simmons CA. 2009. Aortic valve mechanics: An emerging role for the endothelium. J Am Coll Cardiol 53: 1456-1458.
36. Simmons CA, Grant GR, Manduchi E, Davies PF. 2005. Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res 96: 792-799.
37. Soini Y, Salo T, Satta J. 2003. Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. Hum Pathol 34: 756-763.
38. Speer MY, Chien YC, Quan M, Yang HY, Vali H, McKee MD, Giachelli CM. 2005. Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro. Cardiovasc Res 66: 324-333.
39. Taylor PM, Batten P, Brand NJ, Thomas PS, Yacoub MH. 2003. The cardiac valve interstitial cell. Int J Biochem Cell Biol 35: 113-118.
40. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC, Jr., Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. 2006. Heart disease and stroke statistics-2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113: e85-e151.
41. Tuck AB, Chambers AF, Allan AL. 2007. Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management. J Cell Biochem 102: 859-868.
42. Yetkin E, Waltenberger J. 2009. Molecular and cellular mechanisms of aortic stenosis. Int J Cardiol 135: 4-13.
43. Yu PJ, Skolnick A, Ferrari G, Heretis K, Mignatti P, Pintucci G, Rosenzweig B, Diaz-Cartelle J, Kronzon I, Perk G, Pass HI, Galloway AC, Grossi EA, Grau JB. 2009. Correlation between plasma osteopontin levels and aortic valve calcification: Potential insights into the pathogenesis of aortic valve calcification and stenosis. J Thorac Cardiovasc Surg 138: 196-199.